1,329 calculators and references across 60 specialties, with formula confidence shown up front.
ADHERE Classification and Regression Tree (CART) — explanation and clinical context The ADHERE CART is a simple bedside decision tree developed from the Acute Decompensated Heart Failure National Registry to estimate the risk of in-hospital mortality for patients hospitalized with acute decompensated heart failure. The CART analysis identified three sequential admission variables that provided the best discrimination
AFIRE Study Algorithm — Practical explanation and context This calculator applies the core enrollment and outcome insights from the AFIRE randomized trial (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) to provide a pragmatic recommendation: patients with atrial fibrillation and stable CAD who are at least 1 year past revascularization (or have angiographical
AHEAD score - Explanation and clinical context The AHEAD score is a simple bedside risk classification tool developed to estimate short- and long-term prognosis in patients hospitalized for acute heart failure. It includes five binary items (each scores 1 point): Atrial fibrillation (present on admission or known AF), Haemoglobin below sex-specific thresholds (<130 g/L in men; <120 g/L in women), Elderly age (age > 7
ARISTOTLE HF Subgroup Outcome Index: Rationale and clinical context The original ARISTOTLE trial (apixaban vs warfarin) and its biomarker substudies showed that age, a clinical history of heart failure, and circulating biomarkers — notably NT-proBNP, high-sensitivity cardiac troponin, and growth differentiation factor-15 (GDF-15) — were among the strongest predictors of death and heart-failure related events in patie
AUGUSTUS Antithrombotic Strategy – Explanation and Clinical Context The AUGUSTUS randomized trial (2×2 factorial) compared apixaban versus a vitamin K antagonist and aspirin versus placebo in patients with atrial fibrillation and recent acute coronary syndrome and/or percutaneous coronary intervention who were taking a P2Y12 inhibitor. The principal findings were that apixaban (vs VKA) reduced clinically relevant ble